Sustained complete remission after chemobiohormonal therapy for metastatic melanoma

被引：3

作者：

Stein, ME

Bernstein, Z

Drumea, K

Zalik, M

Shklar, Z

Steiner, M

Haim, N

机构：

[1] Rambam Med Ctr, No Israel Oncol Ctr, IL-31096 Haifa, Israel

[2] Technion Israel Inst Technol, Fac Med, Haifa, Israel

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1999年 / 22卷 / 01期

关键词：

chemobiohormonal treatment; complete remission; metastatic melanoma;

D O I：

10.1097/00000421-199902000-00015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The combination of carmustine, cisplatin, dacarbazine interferon, and low-dose tamoxifen is widely used in treating metastatic melanoma and was originally reported to acheive a 20% complete response rate. Among 29 patients who completed the authors' phase TI study with the regimen, five (17%) achieved complete remission, and the median duration of response was 8 months (range, 2-14 months). The aim of the study was to evaluate briefly the value and toxicity of this regimen in treating metastatic malignant melanoma.

引用

页码：62 / 64

页数：3